

Hanza - Expanding in the Northeast

Redeye takes a positive stance towards Hanza's acquisition of Leden. The ~2x net debt 2025e is well within healthy territory - although a weaker market than expected would likely result in a lower EBITDA and the product, customer, and geographic rationales are clear and align well with Hanza's strategy.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Hanza - Expanding in the Northeast